Newsha Nikzad
@NewshaN27
Followers
59
Following
94
Media
4
Statuses
32
PGY-3 @UChicagoMed | @BCMHouston | @RiceUniversity | Interested in palliative hepatology, bioethics, and health equity.
Chicago, IL
Joined May 2024
Thank you to our members and allies for joining us at @AmCollegeGastro @RainbowinGastro reception! So much fun seeing a vision for an event come to life 🤩. Congrats to our Trainee Travel Award Recipients @NewshaN27 and Cass Condray!
1
4
11
Thank you @AmCollegeGastro, my mentors, and colleagues for a wonderful experience at #ACG2025 - it is a privilege to learn from and share our work with this community. @IBDMD @doctornikkid @RainbowinGastro @UChicagoGI
1
3
11
GI Toolkit for Gastroparesis (more than prokinetics) ▪️Ondansetron 8 mg TID ▪️Granisetron patch 34 mg weekly ▪️Prochlorperazine 5-10 mg QID ▪️Chlorpromazine 10-25 mg QID ▪️Scopolamine patch q3d ▪️Aprepitant 80 mg QD ▪️Meclizine 12.5-25 mg TID ▪️Dronabinol 5-10 mg TID #ACG2025
4
139
515
Hardly anyone with MASLD is aware they have a liver condition And only 1 in 10 people with advanced liver disease know it https://t.co/rQcqi2DcC5
@HepCommJournal @peow_u
journals.lww.com
An abstract is unavailable.
3
9
25
New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors Yanofsky, et al. 📕 https://t.co/AhFT4dHHqR
@RussellYanofsky @NewshaN27 @IBDPharmD @IBDMD @MLongMD @JasmohanBajaj
0
7
10
🌟 Hats off to Newsha Nikzad @NewshaN27 of The University of Chicago Medicine @UChicagoMed — the 2025 #AASLDFoundation Bruce A. Luxon #EmergingLiverScholar! #LiverTwitter
https://t.co/spYSpZhaBl
0
2
13
🎉 Congrats to @Phillip_H_Chen & @HowardTLeeMD for presenting our national survey at #WTC2025! This work highlights current practices & perceptions around SOGI data collection 🌈across transplant programs. Honored to be part of this important step toward transplant care equity!
0
6
17
Incredibly grateful to @AASLDFoundation for selecting me as the Bruce A. Luxon Emerging Liver Scholar Thank you so much to Dr. Sonali Paul and Dr. @doctornikkid for their support Excited to meet everyone and represent @UChicagoGI @MedChiefs at #TLM2025
#GITwitter @AASLDtweets
7
4
49
1/ Do clinical outcomes differ across steatotic liver disease subtypes? In @JAMAInternalMed, we report the incidence of adverse liver outcomes, cardiovascular events, and all-cause mortality across MASLD, MetALD, and ALD @RhubbBstat @KaplanDeLiver @SerperM ⬇️
Patients with metabolic dysfunction and alcohol-associated liver disease and alcohol-associated liver disease have modestly higher risks of major adverse liver outcomes and all-cause mortality compared to those with MASLD. https://t.co/T1pGSbZOy0
2
10
27
Naltrexone is not contraindicated in cirrhosis There is no evidence of harm Only evidence of benefit Do we know for certain it is safe in Child C cirrhosis? No! Nothing is certain in child C cirrhosis.
An important message on naltrexone in patients with liver disease: ✅Naltrexone can help reduce alcohol use without harming the liver. 🚫Alcohol DOES harm the liver. We do not need any more barriers to treat patients with AUD➕ALD! @nejm @ebtapper
https://t.co/BhrJHRkOSO
3
16
61
In our latest Short Clinical Review, @NewshaN27, @doctornikkid, and @danielhuynhhh guide you through effectively discussing lifestyle interventions with patients with #MASLD. https://t.co/UGgOKpEuJP
@TrieuMD
1
5
7
Do conversations about prognosis (defined as "conversation with your hepatologist about the likely outcome of your liver disease over time") cause patients w/ cirrhosis to lose hope? Simple answer: No Work led by🌟@donlan_john in @AGA_CGH @AmerGastroAssn
cghjournal.org
Timely prognostic communication is a critical component of care for patients with decompensated cirrhosis (DC). However, few studies have examined the association of prognostic communication with...
Excited to announce our new study published in @AGA_CGH #palliativehepatology Patients w/ cirrhosis highly value timely prognostic communication. Yet, 81% of the 218 pts in our study never discussed end-of-life care wishes with their hepatologist. https://t.co/g0wNVsOHyR
1
9
29
Thank you @AmCollegeGastro for the amazing opportunity to attend and present at #ACG2024 Thank you @aiaronsohn for making this experience and poster possible! As always, I’m incredibly grateful for the ongoing guidance and support of my mentors (pictured and not) @spaulliver
1
3
23
Incredibly proud of my co-exec director of @RainbowinGastro and mentor/role model/friend @spaulliver on your DEI award last night— so deserving and excited to have celebrated with you and Cathy! #DiversityInGI @AmCollegeGastro #LGBTQ
4
8
79
Life-prolonging measures might undermine patient values and engender undue financial distress for patients and their families, write Newsha Nikzad, MD, Joelle Robertson-Preidler, PhD, MA, Faith E. Fletcher, PhD, MA:
journalofethics.ama-assn.org
Racial and ethnic inequity exists throughout the lifespan, including at the end of life.
1
3
3
Love that this is highlighted- important work spearheaded by Newsha Nikrad and @spaulliver @UChicagoMed @UChicagoGI
#ILTSVanguard Article of the Week: From 'American Journal of Transplantation' Considerations in Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Patients Undergoing Liver Transplantation #LiverTransplantation #LiverTwitter
https://t.co/PbO4G6jaV9
1
2
10
One week ago at @DDWMeeting ! I am so grateful to all of my mentors who guide and encourage my flourishing research interests. It is a privilege to continue to engage with and learn from this amazing community. #DDW2024
0
0
4
This COMMENT by Nikzad, @doctornikkid & @spaulliver highlights the need for culturally safe engagement with sexual and gender minority populations, and provides practical advice for clinicians to improve cultural safety for #LGTBQIA+ patients https://t.co/0woRoBS9QV
1
2
9